EP1237895A2 - Phosphorylierung von terminalen primären alkohol- gruppen - Google Patents

Phosphorylierung von terminalen primären alkohol- gruppen

Info

Publication number
EP1237895A2
EP1237895A2 EP00979764A EP00979764A EP1237895A2 EP 1237895 A2 EP1237895 A2 EP 1237895A2 EP 00979764 A EP00979764 A EP 00979764A EP 00979764 A EP00979764 A EP 00979764A EP 1237895 A2 EP1237895 A2 EP 1237895A2
Authority
EP
European Patent Office
Prior art keywords
isoxazol
oxazolidin
difluorophenyl
yloxymethyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00979764A
Other languages
English (en)
French (fr)
Inventor
Michael Barry Gravestock
Kenneth Edwin Herbert Warren
David Simon Ennis
Angela Charlotte Currie
Debra Ainge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1237895A2 publication Critical patent/EP1237895A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems

Definitions

  • the invention relates to chemical processes and chemical intermediates. More particularly, it relates to processes and intermediates which are useful in the selective formation of a primary mono-phosphoryl group in a terminal- 1 ,2-diol-propanoyl containing system, most particularly certain oxazolidinone anti-Gram positive bacterial agents containing such functionality.
  • the invention also relates to processes for the manufacture of said intermediates and to processes for the manufacture of such oxazolidinone compounds utilising said intermediates.
  • Co-pending International Patent Application No. GB99/01753 (WO 99/64417) describes a new class of antibacterial oxazolidinone compounds which are effective as anti- Gram positive bacterial agents, and certain processes for their preparation. Of the compounds disclosed, those of the formula (I) are included :
  • HET is a C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S, which ring is optionally substituted on an available carbon atom by 1 or 2 substituents independently selected from (l-4C)alkyl, amino, (l-4C)alkylamino, (1- 4C)alkoxy and halogen, and/or on an available nitrogen atom (provided that the ring is not thereby quaternised) by (l-4C)alkyl;
  • R 2 and R 3 are independently hydrogen or fluoro;
  • Rep is of the formula R 13p CO- (wherein R 13p is (l-lOC)alkyl substituted by two or more hydroxy groups; 2 of which are in a 1,2-diol orientation, ie. there is a terminal primary alcohol with an adjacent secondary alcohol), or pharmaceutically-acceptable salts, or in-vivo- hydrolysable esters thereof.
  • R 13p is (l-lOC)alkyl substituted by two or more hydroxy groups; 2 of which are in a 1,2-diol orientation, ie. there is a terminal primary alcohol with an adjacent secondary alcohol
  • pharmaceutically-acceptable salts or in-vivo- hydrolysable esters thereof.
  • In-vivo hydro lysable esters include compounds of formula (I) and (I-l) in which any free hydroxy group independently forms a phosphoryl ester of the formula (PD3) :
  • those of formula (I-l) are the pharmaceutically active anti-bacterial enantiomer.
  • the pure enantiomer depicted in (I-l), or mixtures of the 5R and 5S enantiomers, for example a racemic mixture are included in GB99/01753. If a mixture of enantiomers is used, a larger amount (depending upon the ratio of the enantiomers) will be required to achieve the same effect as the same weight of the pharmaceutically active enantiomer.
  • the enantiomer depicted below is the 5R enantiomer.
  • the preparation described includes isolation of the primary mono-phosphoryl compound (Intermediate Example 15) from a mixture of compounds (including, for example, the bis- phosphoryl and cyclic phosphoryl compounds) by use of Medium Pressure Liquid Chromatography using ethyl acetate as the eluant.
  • Other compounds of formula (I) and (I-l) above may be prepared using analagous chemistry.
  • the detailed chemistry and reaction conditions employed is described in the accompanying non-limiting Examples, or is within the skill of the ordinary organic/medicinal chemist (see also WO 97/30995, the relevant process sections of which are inco ⁇ orated herein, for details on prepartion of certain intermediates).
  • GB99/01753 discloses that for a compound of formula (I) and (I-l) containing a number of free hydroxy groups, those groups not being converted into a prodrug functionality may be protected (for example, using a t- butyl-dimethylsilyl group), and later deprotected. Also, enzymatic methods may be used to selectively phosphorylate or dephosphorylate alcohol functionalities.
  • the prodrugs containing groups (PD3) may be prepared by reaction of a compound of formula (I) and (I- 1 ) containing suitable hydroxy group/s with a suitably protected phosphorylating agent (for example, containing a chloro or dialkylamino leaving group), followed by oxidation (if necessary) and deprotection.
  • the "Existing Route" to the said compound although satisfactory, is not particularly suitable for the manufacture of large quantities of such products.
  • Selectivity of reaction is important and can impact upon the yield of desired product obtained. Poor selectivity can also lead to the formation of undesired by-products which require removal.
  • the "Existing Route” has potential difficulties associated with the selective formation, in good yield, of the primary mono-phosphoryl/secondary hydroxy moiety.
  • Suitable leaving groups include halo (e.g. iodo, bromo, chloro), triflate or enol phosphate.
  • the protected aniline used as the initial starting material may alternatively be protected as -N-[SiR 3 ] 2 where each R is independently a (l-4C)alkyl group, eg. -N-(SiMe 3 ) 2 .
  • R is independently a (l-4C)alkyl group
  • -N-(SiMe 3 ) 2 we have now discovered a number of further, convenient and useful, processes for the manufacture of said compound (and by analogy other compounds of formula (I) and (I- 1)), which reduces and/or converges the number of reaction stages and, reduces or removes the need for chromatographic purification of intermediates and/or final products.
  • the invention also relates to the application of the chemistry described herein to any system requiring formation of a primary mono-phosphoryl group in a terminal- 1 ,2-diol-propanoyl containing system (such as, for example, 2,3-dihydroxypropanoyl and 3,4-dihydroxy-2-oxo- butyl).
  • a terminal- 1 ,2-diol-propanoyl containing system such as, for example, 2,3-dihydroxypropanoyl and 3,4-dihydroxy-2-oxo- butyl.
  • the invention relates to such 1 ,2-diol-propanoyl containing systems in a compound of formula (I) and (I-l), and most particularly to the said compound.
  • the invention also relates to 1,2-diol-propanoyl containing systems in a compound of formula (I) and (I-l) wherein HET is a C-linked 6-membered heteroaryl ring containing 1 or 2 N, which ring is optionally substituted on any available C atom (provided that when the N atom is adjacent to the link, there is no substitution on any C atom that is adjacent to this N atom) by 1, 2 or 3 substituents independently selected from (l-4C)alkyl, amino, (l-4C)alkylamino, (l-4C)alkoxy, (l-4C)alkoxycarbonyl and halogen.
  • Preferred 6- membered heteroaryl rings are pyridin-2-yl, pyridazin-3-yl or pyrazin-2-yl.
  • the invention also relates to 1,2-diol-propanoyl containing systems in a compound of formula (I) and (I-l) wherein HET is a C-linked 5- or 6-membered heteroaryl ring as described herein, wherein the link to the oxazolidinone ring is via a thiomethyl (-CH 2 - S-) link rather than an oxymethyl (-CH 2 -O-) link (see claim 2 for compounds of formula(I-2)).
  • the invention may also be used in 1 ,2-diol-propanoyl containing systems in a compound of formula (I) and (I-l) wherein HET is a C-linked 5- or 6-membered heteroaryl ring as described in WO 00/21960 (inco ⁇ orated herein by reference), wherein the link to the oxazolidinone ring is via an aminomethyl (-CH 2 -NH 2 -) link.
  • HET is a C-linked 5- or 6-membered heteroaryl ring as described in WO 00/21960 (inco ⁇ orated herein by reference), wherein the link to the oxazolidinone ring is via an aminomethyl (-CH 2 -NH 2 -) link.
  • protecting groups have been referred to.
  • protecting groups see one of the many general texts on the subject, for example, 'Protective Groups in Organic Synthesis' by Theodora Green (publisher: John Wiley & Sons).
  • Protecting groups may be used and removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.
  • the Schemes may be genericised to cover other analogous compounds of formula (I) and (I-l) and (1-2) mentioned herein (see claim 2 for (1-2)). Furthermore, the invention also relates to the application of the chemistry described herein to any system requiring formation of a primary mono-phosphoryl group (-OPO(OH) 2 ) in a terminal- 1 ,2-diol- propanoyl (HO-CH 2 CH(OH)-CO-) containing system.
  • -OPO(OH) 2 a primary mono-phosphoryl group
  • HO-CH 2 CH(OH)-CO- a terminal- 1 ,2-diol- propanoyl
  • a particularly preferred process is that illustrated in Scheme 2B.
  • the use of the hydroxy acid (2H) allows the formation of a protected primary 1 ,2-diol species (PgO- CH 2 CH(OH)-CO-, wherein Pg is a protecting group suitable for protecting alcohols and removable by acid, such as, for example, t-butyl, as in Compound (21) in the case of the said compound).
  • Pg is a protecting group suitable for protecting alcohols and removable by acid, such as, for example, t-butyl, as in Compound (21) in the case of the said compound.
  • the secondary phosphoryl compound which may be optionally protected, for example in the form of a phosphate ester, such as the t-butyl ester as in Compound (2J) in the case of the said compound).
  • the secondary phosphoryl compound is in the form of a phosphate ester.
  • a secondary phosphoryl compound suitable for use in the process may be obtained, for example, by standard phosphorylation chemistry, for example as described herein, using tert-butyl tetraethylphosphorodiimidite, or using phosphorous oxychloride or
  • Scheme 3C is particularly preferred, and offers the advantageous use of the hydroxy acid (2H) to give the protected primary alcohol, and then selective secondary phosphorylation to give (3D); followed by coupling, and then by deprotection of the protected primary alcohol & predominant rearrangement of the secondary phosphoryl compound to the primary phosphoryl compound.
  • Scheme 3C offers a particularly favourable route to the said compound, comprising comparatively few reaction stages in a convergent fashion.
  • the coupling reaction of Schemes 3A to 3D may be carried out in the presence of a suitable base, for example, nBuLi at ca.
  • a suitable inert solvent or diluent such as, for example, dimethylsulphoxide, 1 ,2-dimethoxyethane, tetrahydrofuran (THF), tetrahydropyran, diglyme or toluene.
  • a preferred solvent is a mixture of THF and toluene.
  • Schemes 3 A to 3D may also be achieved via Grignard chemistry, using, for example, an appropriate 4-bromo-phenyl compound in place of (IF).
  • the starting materials for the reactions described herein may be obtained as described herein, or by analogy to such methods, or by standard procedures of organic chemistry.
  • Intermediates (IE) and (IF) are preferred intermediates, especially (IF). 2.
  • a leaving group other than Br could also be used.
  • allyl alcohol could be used and the substitution performed in a reverse sense to that shown with a leaving group (e.g. chloro or mesylate) on (IB).
  • Nosylate and mesylate may also be used in place of tosylate in the epoxide (IH- 1). Preferably nosylate is used.
  • Example 1 shows retention of stereochemistry, i.e. (R)- and (S)-glycidyl nosylate give, respectively, (R)-, (S)- glycidyl ether product.
  • the other epoxide isomer may be used as a starting material. If a racemate is obtained, chiral resolution/chromatography may be used to obtain the desired isomer.
  • DIPEA is di-isopropyl-ethylamine.
  • non-bulky protecting groups in place of t-Bu may be used in (2G) and (2H), for example, any (l-4C)alkyl group; any silyl group (for example trimethylsilyl); or a benzyl group (e.g. using acid catalysed removal, or a reductive removal using e.g. hydrogenation).
  • (2F) may be converted at ambient temperature to, for example, the disodium salt by treatment with 2 mol.eq. sodium carbonate and working-up in acetone and then IMS. 5.
  • (IK) may be prepared as shown in the Existing Route Scheme or as described in
  • Example 4 hereinafter, in which, for example, Intermediate Example 2 may be prepared as follows :-
  • a solution of 3,5-difluoroaniline in THF is chilled to -70°C.
  • a solution of n-butyl lithium in toluene is added and chlorotrimethylsilane then added to complete the bis- trimethylsilyl protection of 3,5-difluoroaniline.
  • a solution of n-butyl lithium in toluene is added to the chilled solution and a solution of l-benzyl-4-piperidone in toluene then added whilst maintaining the temperature.
  • a solution of aqueous hydrochloric acid is added.
  • the aqueous layer of the alcohol intermediate (Intermediate Example 1) is separated and heated to reflux while simultaneously distilling out tetrahydrofuran to complete the formation of Intermediate
  • Example 2 The reaction is then diluted with water and butanol before adjusting the pH with aqueous ammonia at 40°C. The aqueous layer is separated and discarded. Cyclohexane is added to the organic phase to precipitate the product, which is then filtered off after cooling to ambient temperature, washed with a butanol/cyclohexane mixture, cyclohexane and dried under vacuum.
  • Intermediate Example 4 may be prepared as described in Example 4 hereinafter, or using a solution of n-butyl lithium in toluene.
  • (21) may be converted to Diol (2D) by deprotection, for example using acid conditions, such as HCl/dioxan.
  • Hydrogen peroxide may be used in place of mCPBA in the conversion of (21) to
  • reaction is performed in a suitable solvent, such as dioxan.
  • R includes (l-4C)alkyl, for example, methyl, ethyl, propyl, iso-propyl, butyl, iso- butyl, tert-butyl; hydrogen and benzyl.
  • (l-4C)alkyl includes both straight-chain and branched-chain alkyl groups.
  • references to individual alkyl groups such as
  • the lithiated compound may be transmetallated with, for example titanium chloride, titanium i-propoxide or cerium chloride at a tempertaure of about -30°C. Such transmetallation restricts enolisation of the piperidinone and so aids reaction at the desired centre.
  • (3B) may be prepared from (2B) - see scheme 2A - using standard chemistry.
  • (2H) may be prepared from O-t-Bu-serine (2G) using standard chemistry - see
  • DMF is N,N-dimethylformamide
  • DMA is
  • Mobile phase A 10 mM ammonium acetate pH 4.5.
  • Mobile phase B 10 mM ammonium acetate pH 4.5 in 90% acetonitrile.
  • MIBK - DMF, acetone, toluene, MeCN, DME, NMP, THF, EtOAc, TBME, EtOH, MeOH.
  • the following bases have also been used in the coupling reaction in place of caesium carbonate:- NaH, K 2 CO 3 , NaOH, NaOMe, NaOEt, KOMe, KOEt, KO'Bu, LDA, NEt 3 , NBu 3 , NPr 2 Et.
  • 3-Hydroxyisoxazole may be prepared by cyclisation of CH ⁇ C-CO-NHOH (prepared from CH ⁇ C-CO-O-(l-4C)alkyl) as described in Chem.Pharm.Bull. Japan, 14, 92, (1966).
  • 3-Hydroxyisoxazole may also be prepared as follows :- Hydroxylamine hydrochloride is neutralised with sodium hydroxide to liberate the free base. Ethyl propiolate in EtOH is then added dropwise maintaining the reaction temperature at 20-25°C and the reaction stirred before gradually warming to 50-55°C. Heating is continued at 50-55°C for 2.5h and the reaction is then acidified to pH ⁇ 3 with cone. HC1. On complete addition ca. 90% of the ethanol in the reaction is removed by distillation and the residue extracted with warm toluene. Toluene is removed by distillation to precipitate 3- hydroxyisoxazole, and the precipitation is completed by addition of cyclohexane. The resulting suspension is cooled and filtered prior to the material being dried in vacuo at ambient temperature.
  • hydroxylamine hydrochloride is neutralised with sodium hydroxide.
  • the hydroxylamine free base is reacted with a solution of ethyl propiolate in THF at 55 °C.
  • the reaction mixture is cooled and acidified with hydrochloric acid, and the resulting solution extracted with butyronitrile, washed with dilute hydrochloric acid and the organic solution concentrated under reduced pressure to remove ethanol, THF and water.
  • the solution may be used directly in a next stage.
  • N-benzyloxycarbonyl-3,5-difluoroaniline intermediate is prepared by reaction of
  • reaction mixture was cooled to 20-25 °C, and was washed with H 2 O (20 mL).
  • the organic layer was separated, dried (MgSO 4 ) and was concentrated to give crude product that was purified by flash chromatography to give the desired product (IJ) (1.5g, 53 %).
  • Mobile phase A 0.1% TFA in water.
  • Mobile phase B 0.1% TFA in 90 % MeCN.
  • Toluene - MIBK, THF, Toluene, TBME.
  • HPLC showed 56% conversion to l-[4-(l-benzyl- l,2,3,6-tetrahydro-pyridin-4-yl)-3,5-difluoro-phenylamino]-3-(isoxazol-3-yloxy)-propan-2-ol (with reference to an external standard isolated in another reaction, which may be prepared by hydrolysis of Compound (IJ)).
  • HPLC retention time (see below) 2.1 min.
  • Mobile phase A 0.1% TFA in water.
  • Mobile phase B 0.1% TFA in 90 % MeCN.
  • THF was cooled to -70°C under nitrogen and 8.80ml of 1.6M nBuLi in hexanes (14.08mmol) added dropwise at the same temperature. After 20 minutes at the same temperature a solution of (R)-glycidyl butyrate (2.00g, 13.88mmol in 5ml THF) was added dropwise and the mixture stirred for 30 minutes at -70°C, and then stirred to ambient temperature overnight.
  • Example 4 (2.6g, 6.5mmol), 3-hydroxyisoxazole (see Example 1; 0.60g, 7.06mmol), triphenylphosphine (1.96g, 7.48mmol) and diisopropylazodicarboxylate (1.44g, 7.13mmol) in THF (40ml) were reacted using the general method of Example 1.
  • the resultant product was purified by flash chromatograpy (Merck 9385 silica, EtOAc / isohexane (3:2) eluant initially, then repeated using methyl tert-butylether eluant) to give the title product (2.6g, 86%) as a gum.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
EP00979764A 1999-12-03 2000-11-28 Phosphorylierung von terminalen primären alkohol- gruppen Withdrawn EP1237895A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9928499 1999-12-03
GBGB9928499.4A GB9928499D0 (en) 1999-12-03 1999-12-03 Chemical processes and intermediates
PCT/GB2000/004527 WO2001040236A2 (en) 1999-12-03 2000-11-28 Phosphorylation of terminal primary alcohol groups

Publications (1)

Publication Number Publication Date
EP1237895A2 true EP1237895A2 (de) 2002-09-11

Family

ID=10865576

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00979764A Withdrawn EP1237895A2 (de) 1999-12-03 2000-11-28 Phosphorylierung von terminalen primären alkohol- gruppen

Country Status (22)

Country Link
EP (1) EP1237895A2 (de)
JP (1) JP2003515539A (de)
KR (1) KR20020058072A (de)
CN (1) CN1433421A (de)
AR (1) AR026700A1 (de)
AU (1) AU762241B2 (de)
BG (1) BG106728A (de)
BR (1) BR0016087A (de)
CA (1) CA2395052A1 (de)
CO (1) CO5271712A1 (de)
CZ (1) CZ20021912A3 (de)
EE (1) EE200200282A (de)
GB (1) GB9928499D0 (de)
HU (1) HUP0204052A2 (de)
IL (1) IL149641A0 (de)
IS (1) IS6401A (de)
MX (1) MXPA02005396A (de)
NO (1) NO20022605L (de)
PL (1) PL364762A1 (de)
SK (1) SK7862002A3 (de)
WO (1) WO2001040236A2 (de)
ZA (1) ZA200203876B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0113297D0 (en) * 2001-06-01 2001-07-25 Astrazeneca Ab Chemical Process
EP1427711B1 (de) 2001-09-11 2005-07-13 AstraZeneca AB Oxazolidinon- und/oder isoxazolinderivate als antibakterielle mittel
EP1443930A1 (de) 2001-10-25 2004-08-11 AstraZeneca AB Isoxazolinderivative verwendbar als antimikrobielle agenzien
AR038536A1 (es) 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
US7141588B2 (en) 2002-02-25 2006-11-28 Pfizer, Inc. N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
US7473699B2 (en) 2002-02-28 2009-01-06 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents
EP1480975A2 (de) 2002-02-28 2004-12-01 Astrazeneca AB Chemische verbindungen
US7094900B2 (en) 2002-08-12 2006-08-22 Pharmacia & Upjohn Company Llc N-Aryl-2-oxazolidinones and their derivatives
TW200420573A (en) 2002-09-26 2004-10-16 Rib X Pharmaceuticals Inc Bifunctional heterocyclic compounds and methods of making and using same
EP1565186B1 (de) 2002-11-21 2006-11-02 Pharmacia & Upjohn Company LLC N-(4-(piperazin-1-yl)-phenyl-2-oxazolidinon-5-carbonsäureamid-derivate und verwandte verbindungen als antibakterielle mittel
US8324398B2 (en) 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
EP2492264A3 (de) 2003-06-03 2012-12-19 Rib-X Pharmaceuticals, Inc. Heterocyclische Biarylverbindungen Und Verfahren Zu Deren Herstellung Und Anwendung
US7304050B2 (en) 2003-09-16 2007-12-04 Pfizer Inc. Antibacterial agents
TW200526649A (en) 2003-12-17 2005-08-16 Rib X Pharmaceuticals Inc Halogenated biaryl heterocyclic compounds and methods of making and using the same
JP5383037B2 (ja) 2004-02-27 2014-01-08 リブ−エックス ファーマシューティカルズ，インコーポレイテッド 大環状化合物およびそれらを製造し使用する方法
JP5534497B2 (ja) 2005-06-08 2014-07-02 メリンタ セラピューティクス，インコーポレイテッド トリアゾール類の合成方法
CA2664572C (en) 2006-09-25 2015-06-16 Wockhardt Research Centre Substituted piperidinophenyl oxazolidinones
WO2014014845A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1311787A (zh) * 1998-06-05 2001-09-05 阿斯特拉曾尼卡有限公司 噁唑烷酮衍生物、其制备方法以及含有它们的药物组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0140236A2 *

Also Published As

Publication number Publication date
WO2001040236A2 (en) 2001-06-07
IL149641A0 (en) 2002-11-10
CZ20021912A3 (cs) 2002-08-14
WO2001040236A3 (en) 2002-05-10
NO20022605L (no) 2002-06-26
JP2003515539A (ja) 2003-05-07
BR0016087A (pt) 2002-08-06
AU762241B2 (en) 2003-06-19
BG106728A (en) 2003-02-28
CO5271712A1 (es) 2003-04-30
EE200200282A (et) 2003-06-16
CN1433421A (zh) 2003-07-30
MXPA02005396A (es) 2002-11-29
ZA200203876B (en) 2003-08-15
NO20022605D0 (no) 2002-05-31
SK7862002A3 (en) 2003-02-04
KR20020058072A (ko) 2002-07-12
IS6401A (is) 2002-05-28
AU1715601A (en) 2001-06-12
HUP0204052A2 (hu) 2003-03-28
CA2395052A1 (en) 2001-06-07
AR026700A1 (es) 2003-02-26
GB9928499D0 (en) 2000-02-02
PL364762A1 (en) 2004-12-13

Similar Documents

Publication Publication Date Title
AU762241B2 (en) Chemical processes and intermediates
JP7030749B2 (ja) 不斉補助基
US8470987B2 (en) Protective group for synthesis of RNA and derivative
US6617339B1 (en) Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
FR3037958A1 (de)
JPH08301869A (ja) ヘテロ原子−含有ベンゾシクロペンタン−オキサゾリジノン
PL183512B1 (pl) Przeciwbakteryjne fenylooksazolidynony
KR20050106064A (ko) 항생제로서 유용한 히드록시메틸 치환 디히드로이속사졸유도체
KR20010085887A (ko) 항균제로서의 헤테로시클릭 아미노 메틸옥사 졸리디논
US20240239833A1 (en) Alkoxyphenyl derivatives, protected nucleosides and protected nucleotides, method for producing oligonucleotides, and method for removing substituents
EP3560925B1 (de) Neuartige verbindung und pharmazeutisch verträgliches salz davon
JP2008500318A (ja) 抗菌剤としての３−｛４−（ピリジン−３−イル）フェニル｝−５−（１ｈ−１，２，３−トリアゾール−１−イルメチル）−１，３−オキサゾリジン−２−オン
MXPA06013540A (es) Derivados de 3-(4-(2 -dihidroisoxasol -3-ilpiridin-5-il) fenil)-5- triazol-1- ilmetiloxazolidin -2-ona como inhibidores de mao para el tratamiento de infecciones bacterianas.
WO2002096916A1 (en) Process for phosphorylation
JPH09500131A (ja) Ｈｉｖプロテアーゼ阻害剤の製造方法
WO2004048370A1 (en) Antibacterial compounds
JP2006520774A (ja) 抗菌性１，３−オキサゾリジン−２−オン誘導体
JP2006520775A (ja) 抗菌性オキサリジノン類

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20021111

17Q First examination report despatched

Effective date: 20030402

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030813

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1049009

Country of ref document: HK